A Novel Diagnostic and Therapeutic Strategy for Cancer Patients by Integrating Chinese Medicine Syndrome Differentiation and Precision Medicine.
10.1007/s11655-022-3671-z
- Author:
Shu-Xian YU
1
;
Zi-Mao LIANG
1
;
Qi-Biao WU
1
;
Lan SHOU
1
;
Xing-Xing HUANG
1
;
Qian-Ru ZHU
1
;
Han XIE
1
;
Ru-Yi MEI
1
;
Ruo-Nan ZHANG
1
;
Xiang-Yang ZHAI
1
;
Tian XIE
1
;
Xin-Bing SUI
2
Author Information
1. School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, 311121, China.
2. School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, College of Medicine, Hangzhou Normal University, Hangzhou, 311121, China. hzzju@hznu.edu.cn.
- Publication Type:Journal Article
- Keywords:
Chinese medicine;
Western medicine;
cancer treatment;
precision medicine;
syndrome differentiation
- MeSH:
Antineoplastic Agents;
Drugs, Chinese Herbal/therapeutic use*;
Humans;
Medicine, Chinese Traditional;
Neoplasms/therapy*;
Precision Medicine;
Syndrome
- From:
Chinese journal of integrative medicine
2022;28(10):867-871
- CountryChina
- Language:English
-
Abstract:
Applying Chinese medicine (CM) is an important strategy for malignant tumor treatment in China. One of the significant characteristics of CM is to treat diseases based on syndrome differentiation. For Western medicine, it is of important clinical significance to formulate guidelines for the diagnosis and treatment of cancer patients based on the characteristics of disease differentiation. In Chinese clinical practice, the combination of disease differentiation and syndrome differentiation is an important feature for cancer treatment in the past. Currently, molecular profiling and genomic analysis-based precision medicine optimizes the anticancer drug design and holds the greatest success in treating cancer patients. Therefore, we want to know which populations of cancer patients can benefit more from CM treatment if the theory of precision medicine is applied to CM clinical practice. So, we developed a novel diagnostic and therapeutic strategy "disease-syndrome differentiation-genomic profiling-prescriptions" for cancer patients by CM syndrome differentiation and precision medicine. As a result, this strategy has greatly enhanced the anti-tumor efficacy of CM and improved clinical outcomes for cancer patients with some gene mutations. Our idea will hopefully establish a novel approach for the inheritance and innovation of CM.
